Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Pediatric corneal cross-linking: comparison of visual and topographic outcomes between conventional and accelerated treatment protocol

Search Title by author or title

Session Details

Session Title: Cross-Linking

Session Date/Time: Sunday 11/09/2016 | 08:00-09:30

Paper Time: 08:00

Venue: Auditorium A

First Author: : P.Baenninger SWITZERLAND

Co Author(s): :    L. Bachmann   L. Wienecke   M. Thiel   C. Kaufmann           

Abstract Details

Purpose:

To compare visual and topographic outcomes 1 year after conventional (C-CXL) versus accelerated corneal crosslinking (A-CXL) in pediatric keratoconus.

Setting:

Retrospective single center study. Augenklinik Luzerner Kantonsspital

Methods:

In 100 patients (age 11-18; 79% male) we compared the changes in uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA) and maximum keratometry values (Kmax) before and 1 year after conventional (n=42, irradiance for 30minutes with 3mW/cm2) versus accelerated (n=58, irradiance for 10 minutes with 9mW/cm2) treatment protocol for CXL. The power to detect a difference in UCVA of 0.05 (non-inferiority margin) between the C-CLX and the A-CLX group after 1 year is 0.966.

Results:

At baseline, groups were not statistically different in terms of visual acuity (UCVA 0.073 (95% CI: -0.046-0.191); p=0.226), BCVA (0.082 (95%CI: -.0302-0.194); p=0.912)) and Kmax (-0.231 (95% CI -2.23-1.769); p=0.819). No statistical difference in UCVA (-0.019 (95% CI: -0.147-0.109); p=0.766), BCVA (-0.012 (95% CI: -0.103-0.079); p=0.797) and Kmax (0.432 (95% CI:-0.910-1.774); p=0.522) was observed between C-CXL and A-CXL after 1 year.

Conclusions:

In pediatric keratoconus, A-CXL was equivalent to C-CXL in terms of efficacy within 1 year.

Financial Disclosure:

NONE

Back to previous